Skip to main content
Back
Watch Compare

Lyell Immunopharma, Inc.

Data quality: 100%
LYEL
NASDAQ Manufacturing Chemicals
$23.84
▲ $0.47 (2.01%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-75.89%

Growth

Revenue Growth (5Y)
-75.89%
Below sector avg (1.82%)
Revenue (1Y)-40.98%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-87.40%
Below sector avg (-54.68%)
ROIC-58.74%
Net Margin-762355.56%
Op. Margin-748344.44%

Safety

Debt / Equity
N/A
Current Ratio10.30
Interest CoverageN/A

Valuation

PE (TTM)
-2.03
Below sector avg (-1.49)
P/B Ratio1.69
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -75.89% annually over 5 years
Negative free cash flow of -150.80 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 34.91%
Capital intensive — 2166.67% of revenue goes to capex

Price History

Financial Trends

Analyst Price Target

5 analysts
Buy
+46.0%
upside to target
Current
$23.84
Consensus Target
$34.80
$12.00
Low
$45.00
High
Forecast
Forward EPS
-$9.16
Est. Revenue
1.89 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$2.26 · Rev Est: 5,500.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$3.60 -$2.89 -$2.13 -$7.68 — —
Estimate -$3.60 -$3.58 -$2.64 -$2.23 -$2.26 -$2.32
Surprise 0.00% +19.35% +19.39% -244.09% — —

Growth

Rev 5Y: -75.89% · Earnings 1Y: N/A
Revenue Growth (1Y) -40.98% Revenue Growth (3Y) -47.38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -75.89% Earnings Growth (5Y) N/A

Profitability

ROE: -87.40% · Net Margin: -762355.56%
Revenue (TTM) 36,000.0 Net Income (TTM) -274.45 M
ROE -87.40% ROA -69.18%
Gross Margin N/A Operating Margin -748344.44%
Net Margin -762355.56% Free Cash Flow (TTM) -150.80 M
ROIC -58.74% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 10.30
Debt / Equity N/A Current Ratio 10.30
Interest Coverage N/A Asset Turnover 0.00
Working Capital 296.32 M Tangible Book Value 329.12 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -2.03 · EV/EBITDA: N/A
P/E Ratio -2.03 Forward P/E N/A
P/B Ratio 1.69 P/S Ratio 15461.54
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 293.77 Fwd Earnings Yield N/A
FCF Yield -27.09%
Market Cap 556.62 M Enterprise Value 433.04 M

Per Share

EPS: -16.06 · FCF/Share: -6.46
EPS (Diluted TTM) -16.06 Revenue / Share 0.00
FCF / Share -6.46 OCF / Share -6.43
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 54.95% · CapEx/Rev: 2166.67%
CapEx / Revenue 2166.67% FCF Conversion 54.95%
SBC-Adj. FCF -174.69 M Growth Momentum 34.91

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 36,000.0 61,000.0 130,000.0 84.68 M 10.65 M
Net Income -274.45 M -342.99 M -234.63 M -183.12 M -250.22 M
EPS (Diluted) -16.06 -1.31 -0.93 -0.74 -1.84
Gross Profit — — — — —
Operating Income -269.40 M -358.76 M -247.01 M -187.06 M -214.78 M
EBITDA — — — — —
R&D Expenses — — 182.95 M 159.19 M 138.69 M
SG&A Expenses — — — — —
D&A 11.54 M 19.63 M 20.25 M 18.02 M 13.62 M
Interest Expense — — — — —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 340.05 M 490.86 M 750.03 M 937.56 M 1.13 B
Total Liabilities 91.85 M 108.04 M 95.08 M 104.31 M 197.62 M
Shareholders' Equity 248.20 M 382.82 M 654.95 M 833.25 M 929.79 M
Total Debt — — — — —
Cash & Equivalents 60.18 M 105.60 M 145.65 M 123.55 M 293.83 M
Current Assets 260.94 M 379.59 M 554.69 M 651.30 M 626.29 M
Current Liabilities 49.41 M 53.79 M 34.52 M 37.03 M 46.74 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -2.0 -1.5
P/B 1.7 1.6
ROE % -87.4 -54.7
Net Margin % -762355.6 -41.5
Rev Growth 5Y % -75.9 1.8
D/E — 0.3

ETFs Holding This Stock
CNCR CNCR
1.01% weight